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Purpose: The assessment of cardiovascular risk is uniformly recommended
as a decision-support for therapies aimed at preventing cardiovascular dis-
eases. The aim of this study was to assess the predictive accuracy of the ESC
SCORE in French general population. 
Methods: Our analysis was based on the Third French MONICA Cross-
sectional population-based survey (from South-Western(SW), North-
Eastern(NE) and Northern(N) France), on cardiovascular risk factors (1995-
1996) and on subjects consecutively referred for cardiovascular check-up to a
Department of Preventive Cardiology (DPC) in a SW French University Hos-
pital since 1995. Vital status was obtained 10 years after inclusion. The 10-
year predicted risk of cardiovascular (CV) death was calculated using the
SCORE equation for low-risk countries and was compared to the 10-year inci-
dence of CV death. 
Results: SCORE equation was applied in 6915 participants aged 35-64
(56% were men) and 56 CV deaths occurred. The CV death rate was
0.67%[95% confidence interval: 0.39-1.13] in DPC and 0.81%[0.42-1.56],
1.10%[0.61-1.98] and 2.00%[1.31-3.05] in SW, NE and N MONICA sample,
respectively. The median risk SCORE was 0.97% and was not significantly
different to the 10-year incidence of CV death (1.05%[0.81-1.37]). The C-sta-
tistic of the SCORE equation in our sample was 79%[73-85]. The median risk
SCORE according to sex, age, educational level, family history of premature
CV disease, physical activity, impaired fasting glucose, smoking, systolic
blood pressure, total cholesterol, LDL-cholesterol, HDL-cholesterol and risk
SCORE was not different to the 10-year incidence of CV death. According to
the cut-point of 5%, 6440 participants(93%) were correctly classified using the
SCORE equation (i.e. subjects with risk SCORE≥5% deceased during the 10-
year period or subjects with risk SCORE<5% non-deceased during the 10-year
period).
Conclusions: In French general population aged 35-64, the SCORE equa-
tion adequately predicts CV death. 
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Background: The 2012 ESC guidelines recommend a LDL-cholesterol
(LDL-C) lower than 3 mmol/L for subjects at low or moderate risk with a
class I/A and a strong grade. According to ESC, statins should be used as the
drugs of first choice. The aim of this study was to assess the association
between elevated LDL-C with total and cardiovascular (CV) mortality in pri-
mary prevention.
Methods: Our study population consisted in patients who had been
admitted from 1995 to 2011 in a preventive cardiology unit of a large French
university hospital. We excluded patients whose age was less than 30 and all
patients with previous ischemic heart disease. Vital status in 2011 was
checked through the death national database.
Results: 4885 patients were included (59% men; 53±10 yrs). After a
mean follow-up of 8.6 years, 129 deaths, including 31 CV deaths, were
recorded. The mean LDL-C was 3.98±1.18 mmol/L (3.90 in men and 4.11
in women). Among these 4885 patients, 2648 (54.2%) had LDL-C lower
than 4 mmol/L, 1890 (38.7%) had LDL-C between 4 and 6 mmol/L, 347
(7.1%) had LDL-C higher than 6 mmol/L, and 1833 (37.5%) were on cur-
rent lipid-lowering treatment. After adjustment for age, gender, smoking,
hypertension and diabetes, an increased LDL-C > 4 mmol/L was signifi-
cantly associated with all cause mortality (hazard ratio (HR) 2.06; 95%
confidence interval (CI) [1.42-3.00], p=0.001) and with CV mortality (HR
2.18; 95% CI [1.04-4.57], p=0.04). After adjustment for these classical
risk factors and for lipid-lowering treatment, LDL-C remained signifi-
cantly associated with an increasing risk of all cause mortality; with LDL-
C < 4 mmol/L as a reference class, LDL-C levels between 4 and 6 mmol/L
were associated with an increased all cause mortality (HR 1.72; 95% CI
[1.17-2.54], p=0.006) as well as LDL-C > 6 mmol/L (HR 2.60; 95% CI
[1.49-4.85], p=0.001).
Conclusions: LDL-C levels higher than 4 mmol/L were significantly asso-
ciated with all-cause and cardiovascular mortality in primary prevention. 
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Purpose: The CHA2DS2-VASc score has been validated and is widely
used to stratify the risk of thromboembolism in patients with non-valvular
atrial fibrillation (AF). We sought to investigate whether this score could
also be useful to predict the risk of stroke and death in patients with valvular
AF.
Methods: Between 1998 and 2011, 1,592 consecutive patients, hospital-
ised for AF, 300 with valvular AF (mitral and/or aortic valve disease) and
1,292 with non-valvular AF were enrolled in the cohort. All patients were
followed-up at least 6 months and cardiovascular events recorded. The end-
point was defined as the first occurrence of stroke or death. The Cox anal-
ysis was adjusted on warfarin, antiplatelet and antiarrhythmic treatments at
discharge.
Results: Mean age was 73±14 years in valvular AF and 68±15 in non-val-
vular AF (p=0.0001). At baseline, in the valvular AF group CHA2DS2-VASc
score were = 0 for 14 (5%) patients, = 1 for 28 (9%), ≥ 2 for 258 (86%). Non-
valvular AF CHA2DS2-VASc scores were = 0 for 158 (12%), = 1 for 189 (15),
≥2 for 945 (73%). The difference was statistically significant (p<0.0001).
During a mean follow-up of 4.6±3.5 years, the patients with valvular AF expe-
rienced 154 (51%) and the patients with non-valvular AF experienced 409
(32%) strokes or deaths. The Kaplan-Meier curves (figure) show that patients
with a CHA2DS2-VASc score ≥2 were at higher risk of stroke or death. The
adjusted Cox model, showed that valvular AF (HR, 1.57, 95%CI 1.30-1.89,
p<0.0001) and a CHA2DS2-VASc score ≥2 (HR, 5.30, 95%CI 3.77-7.45,
p<0.0001) were predictors of risk of stroke or death.
Conclusion: These results suggest that a CHA2DS2-VASc score ≥2 is asso-
ciated with a higher risk of stroke and deaths, at mid-term follow-up, in
patients with valvular AF (figure next page).
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Purpose: There is good evidence that adherence to medical treatment is
enhanced by knowledge and understanding of the drug, its benefits and its
side-effects.
Objectives: To investigate knowledge and perceptions of antithrombotic
therapy among a population of patients receiving chronic anticoagulation
therapy with vitamine k antagonists (VKA) or direct oral anticoagulants
(DOA). 
Methods: We conducted a prospective study among 122 patients admitted
in our cardiology unit and receiving anticoagulant therapy for more than
3 months. Atrial fibrillation was the main indication of therapy (n=63, 51.6%)
and VKA concerned 87% of patients. All patients were invited to fill in a
questionnaire (11 questions), which was handed out by a nurse in a face-to-
face interview. None of the patients refused to fill in the questionnaire, which
was completed at once and independently. 
Results: While the vast majority of patients know that they have anti-
coagulant therapy (96,7%), patients presented a clear lack of knowledge
concerning mainly food and drug interaction (table 1), the possible conse-
quences of under- or over-anticoagulation (n=31; 25,4%), the reason why they
have this therapy (n=39; 32,7%) and how to control their treatment.
Comparing the two therapies, we observed a non significant difference in
knowledge concerning VKA and DOA except knowledge of risks of therapy
which was superior in the DOA group (p<0.05). 
In conclusion: Patients’ anticoagulant therapy knowledge, either vitamin
K antagonists or DOA, is poor. With the increasing use of DOA, from which
we have no more biologic control to assess compliance, improved patient edu-
cation and physician involvement in therapeutic education, is crucial. 
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Anxiety and depressive symptoms after acute coronary syndrome (ACS)
are associated with increased mortality and morbidity, more random cardiac
rehabilitation, unhealthy behaviours. The aim of this study was to determine
prevalence of these symptoms after ACS, and associated factors.
During 6 months, all patients admitted to the Hospital of Reims for ACS
were included. Hospital Anxiety and Depression Score (HADS) was used to
screen anxiodepressive symptoms during initial hospitalization and 3 months
later. The analysis focused on socio-demographic, clinico-biological and ther-
apeutic data. 
We included 101 patients. 40,6% had anxiety and depressive symptoms on
admission and 41,6% at 3 months. Factors associated with a high persistent
3 month score were: initial HADS score (r = 0,81 p<0.001), history of depres-
sion (OR 14,1; CI95% 1,7-42,4 p<0,001), history of coronary heart disease
(OR 5,8; 95% CI95% 1,7-19,6 p<0,001), young age (54,4 years ± 10,9
p 0,039), social isolation (OR 12,5; CI95% 4,2-37,3 p< ,001), smoking (OR
8,7; CI95% 3,5-21,7 p<0.001), physical inactivity (OR 5,1; CI95% 2, 3-10,9
p <0.001), early ventricular arrhythmias (OR 13,5; CI95% 5,1-35,9 p<0,001).
Also high C-reactive protein (OR 11,8; p< 0,001), a low HDL-cholesterol
(mean 0,4g/L p < 0.001), and high level of liver enzyme (OR 0,3; p<0,001)
were associated with positive score. 17 patients have attempted suicide and
2 patients have committed suicide. 
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